Uveal Melanoma Clinical Trial
— AMUMOfficial title:
Adjuvant Melatonin for Uveal Melanoma: A Randomized Open Phase III Study
Uveal melanoma (UM) is the most common type of cancer inside the eyes of adults. Almost half of all patients diagnosed with UM will eventually develop metastases. Once metastases occur, the median patient survival is short. In this trial, we will test if treatment with Melatonin after primary tumor diagnosis can prevent or delay the development of metastases. 100 patients diagnosed with primary UM will be randomized to either treatment with Melatonin tablets (20 mg at night), or to a control group. Both groups will be followed for 5 years. At 5 years, the number of patients that have developed metastases in the Melatonin and control groups will be compared (primary outcome measure).
Status | Recruiting |
Enrollment | 100 |
Est. completion date | January 1, 2031 |
Est. primary completion date | January 1, 2031 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The patient is =18 years 2. The patient has given his/her written informed consent to participate in the trial. 3. The patient has a melanoma originating in the choroid or in the ciliary body, as diagnosed by clinical methods and/or histological examination. AND at least one of the following 7 items: 4. The patient's tumor is of size category T3d or higher, or stage IIIB or IIIC according to the American Joint Committee on Cancer (AJCC, version 8) criteria. 5. The patient's tumor is large according to modified criteria from the Collaborative Ocular Melanoma Study (COMS), i.e. largest basal diameter >16 mm or apical thickness >8 mm. 6. The patient's tumor was of size category T2a before plaque brachytherapy and has then recurred. 7. The patient's tumor has an epithelioid cell type (>5 epithelioid cells per high power field and >90 % of tumor cells epithelioid). 8. The patient's tumor has a low immunohistochemical expression of BAP1. 9. The patient's tumor has more than 9 mitoses per high power field. 10. The patient has >60 % risk of metastases within 5 years, as determined with another published and validated prognostic test (e.g. gene expression class 2). 11. If the patient is already being treated with Melatonin, a two-week wash out period will be applied before randomization. Exclusion Criteria: 1. Oversensitivity or allergy to Melatonin or any of the excipients in the tablet. 2. The patient has metastatic disease, detectable with radiological examinations or any other method (development of metastases after recruitment to the trial does not disqualify the patient from participation). 3. The patient is unable to provide informed consent. 4. The patient has decreased liver function (e.g., liver cirrhosis or hepatitis) 5. The patient is pregnant or a fertile woman (Women of child-bearing potential, WOCBP). Fertility is defined as the time between menarche and menopause for women that are not permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. Menopause is defined as absence of menstruation for 12 months or longer without other cause. 6. The patient is breast feeding or is planning to breastfeed before the end of the trial. Women that are included in the trial and begin to breastfeed before the end of the trial must resign from the trial. 7. The patient has epilepsy. 8. The patient is being treated (for more than 4 weeks) with CYP1A2 inhibitors Fluvoxamine, Ciprofloxacin, Norfloxacin, or Verapamil, with combined hormonal contraception (containing etinylestradiole and progestin), with hormonal substitution therapy, with 5- or 8-metoxypsoralene or cimetidine. If a patient starts using any of these substances for more than 4 weeks after recruitment to the trial, he or she does not need to resign from the trial but may pause the use of Melatonin, and then restart after the use of the other substance has ceased. Concurrent treatment with CYP1A2 inducers including carbamazepine, fenytoine, rifampicin, omeprazole, calcium antagonists, benzodiazepine-related hypnotics, non-steroid anti-inflammatory drugs (NSAIDs) and beta blockers is not an exclusion criterium. Concurrent treatment with warfarin or other vitamin K antagonists is not an exclusion criterium, but requires information to the patient and discussion about dose adjustments with the prescribing physician. 9. The primary UM was diagnosed more than 12 months ago. |
Country | Name | City | State |
---|---|---|---|
Sweden | St. Erik Eye Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Gustav Stalhammar | Karolinska Trial Alliance, Swedish Cancer Society, The Swedish Eye Foundation (Ögonfonden), The Swedish Society of Medicine |
Sweden,
Hagstrom A, Kal Omar R, Williams PA, Stalhammar G. The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature. BMC Cancer. 2022 Apr 13;22(1):398. doi: 10.1186/s12885-022-09464-w. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Interim analysis: Number of patients that develop metastases in Melatonin vs. Control arm, evaluated as relative risk (RR). | Measured as relative risk (i.e., the incidence rate of metastasis in the Melatonin arm divided by the incidence rate in the control group), with 95 % confidence interval. | 3 years | |
Other | Interim analysis: Overall survival (OS) in Melatonin vs. Control arm, evaluated with the Log-rank test. | Overall survival in the Melatonin vs. Control arm | 3 years | |
Primary | Number of patients that develop metastases in Melatonin vs. Control arm, evaluated as relative risk (RR). | Measured as relative risk (i.e., the incidence rate of metastasis in the Melatonin arm divided by the incidence rate in the control group), with 95 % confidence interval. | 5 years | |
Secondary | Number of patients that develop metastases in Melatonin vs. Control arm, evaluated as Cox regression hazard ratio (HR). | Measured as hazard ratio (i.e., the hazard for metastasis in the Melatonin arm divided by the hazard in the control group) with relevant covariates (e.g., tumor size, patient age, BAP-1 expression), with 95 % confidence interval. | 5 years | |
Secondary | Overall survival (OS) time from randomization in Melatonin vs. Control arm, evaluated with the Log-rank test. | Overall survival (the length of time from randomization that patients are still alive) in the Melatonin vs. Control arm. A Kaplan-Meier-curve will be drawn and the Log-rank test will be applied. | 5 years | |
Secondary | Overall survival (OS) time from the detection of metastasis in Melatonin vs. Control arm, evaluated with the Log-rank test. | Overall survival (the length of time from radiological detection of metastases that patients are still alive) in the Melatonin vs. Control arm. A Kaplan-Meier-curve will be drawn and the Log-rank test will be applied. | 5 years | |
Secondary | Number of patients that develop other cancers (i.e., cancer diagnoses other than uveal melanoma) in Melatonin vs. Control arm, evaluated as relative risk (RR). | Measured as relative risk (i.e., the incidence rate of other cancers in the Melatonin arm divided by the incidence rate in the control group), with a 95 % confidence interval. | 5 years | |
Secondary | Number of patients that develop other cancers (i.e., cancer diagnoses other than uveal melanoma) in Melatonin vs. Control arm, evaluated as Cox regression hazard ratio (HR). | Measured as hazard ratio (i.e., the hazard for other cancers in the Melatonin arm divided by the hazard in the control group) with relevant covariates (e.g., tumor size, patient age, BAP-1 expression), with 95 % confidence interval. | 5 years | |
Secondary | Number of participants with treatment-related adverse events (AEs) and serious adverse events (SAEs) in Melatonin vs. Control arm, as assessed by CTCAE v5.0. | Frequency of adverse events (AEs) and serious adverse events (SAEs) in the Melatonin vs. Control arm, evaluated as relative risk (RR) with 95 % confidence interval. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04364230 -
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
|
Phase 1/Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT05542342 -
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
|
Phase 2 | |
Completed |
NCT02849145 -
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
|
N/A | |
Recruiting |
NCT01438658 -
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
|
N/A | |
Not yet recruiting |
NCT00811200 -
Treatment Of Radiation Retinopathy Trial
|
Phase 2/Phase 3 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Recruiting |
NCT05077280 -
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
|
Phase 2 | |
Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Not yet recruiting |
NCT06246149 -
Adjuvant Tebentafusp in High Risk Ocular Melanoma
|
Phase 3 | |
Completed |
NCT01955941 -
Vascular Response to Brachytherapy Using Functional OCT
|
||
Completed |
NCT00661622 -
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
|
Phase 2 | |
Active, not recruiting |
NCT03070392 -
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT06284512 -
Uveal Melanoma - Comparative Study
|
||
Recruiting |
NCT05524935 -
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT02913417 -
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06073548 -
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
|
||
Recruiting |
NCT06075589 -
Psychoeducation for Uveal Melanoma
|